FRA:640 (Hong Kong)
Â
Registered Shs Unitary 144A/Reg S
€
0.60
(0%)
Mar 12
Warning! GuruFocus detected
4 Severe warning signs
with 640.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
China Resources Pharmaceutical Group Ltd
ISIN : HK0000311099
Share Class Description:
FRA:640: Registered Shs Unitary 144A/Reg SCompare
Compare
Traded in other countries / regions
03320.Hong Kong640.GermanyCRPGF.USA IPO Date
2016-11-01Description
China Resources Pharmaceutical is the third-largest medical distributor in China by revenue. It is an integrated pharmaceutical company specializing in research and development, manufacturing, medical distribution, and retail pharmacies. As of 2023, the medical distribution business accounts for 82.6% of its total revenue. CR Pharma's manufacturing business, 17.8% of total revenue, has subsidiaries with a strong presence in traditional Chinese medicine and consumer healthcare.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.81 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 1.58 | |||||
| Debt-to-EBITDA | 4.72 | |||||
| Interest Coverage | 7.41 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 1.49 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.2 | |||||
| 3-Year EBITDA Growth Rate | 10.1 | |||||
| 3-Year EPS without NRI Growth Rate | 13.3 | |||||
| 3-Year FCF Growth Rate | 31.4 | |||||
| 3-Year Book Growth Rate | 2.7 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 5.79 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 12.77 | |||||
| 9-Day RSI | 25.24 | |||||
| 14-Day RSI | 32.92 | |||||
| 3-1 Month Momentum % | -2.31 | |||||
| 6-1 Month Momentum % | 14.41 | |||||
| 12-1 Month Momentum % | 4.1 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.37 | |||||
| Quick Ratio | 1.12 | |||||
| Cash Ratio | 0.43 | |||||
| Days Inventory | 58.47 | |||||
| Days Sales Outstanding | 107.1 | |||||
| Days Payable | 97.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 5.08 | |||||
| Dividend Payout Ratio | 0.2 | |||||
| 3-Year Dividend Growth Rate | 9.9 | |||||
| Forward Dividend Yield % | 5.08 | |||||
| 5-Year Yield-on-Cost % | 7.35 | |||||
| Shareholder Yield % | -31.66 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 15.77 | |||||
| Operating Margin % | 6.31 | |||||
| Net Margin % | 1.5 | |||||
| FCF Margin % | 6.07 | |||||
| ROE % | 7.99 | |||||
| ROA % | 1.47 | |||||
| ROIC % | 9.51 | |||||
| 3-Year ROIIC % | 13.74 | |||||
| ROC (Joel Greenblatt) % | 22.79 | |||||
| ROCE % | 11.24 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 8.32 | |||||
| Forward PE Ratio | 6.51 | |||||
| PE Ratio without NRI | 6.25 | |||||
| Shiller PE Ratio | 8.81 | |||||
| Price-to-Owner-Earnings | 4.27 | |||||
| PEG Ratio | 1.3 | |||||
| PS Ratio | 0.12 | |||||
| PB Ratio | 0.64 | |||||
| Price-to-Tangible-Book | 1.59 | |||||
| Price-to-Free-Cash-Flow | 2 | |||||
| Price-to-Operating-Cash-Flow | 1.67 | |||||
| EV-to-EBIT | 7.16 | |||||
| EV-to-Forward-EBIT | 3.59 | |||||
| EV-to-EBITDA | 5.69 | |||||
| EV-to-Forward-EBITDA | 2.95 | |||||
| EV-to-Revenue | 0.36 | |||||
| EV-to-Forward-Revenue | 0.17 | |||||
| EV-to-FCF | 6.07 | |||||
| Price-to-GF-Value | 0.88 | |||||
| Price-to-Projected-FCF | 0.26 | |||||
| Price-to-DCF (Earnings Based) | 0.41 | |||||
| Price-to-DCF (FCF Based) | 0.06 | |||||
| Price-to-Graham-Number | 0.66 | |||||
| Earnings Yield (Greenblatt) % | 13.99 | |||||
| FCF Yield % | 49.49 | |||||
| Forward Rate of Return (Yacktman) % | 30.06 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
China Resources Pharmaceutical Group Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 32,121.031 | ||
| EPS (TTM) (€) | 0.076 | ||
| Beta | -0.68 | ||
| 3-Year Sharpe Ratio | 0.54 | ||
| 3-Year Sortino Ratio | 1.02 | ||
| Volatility % | 26.09 | ||
| 14-Day RSI | 32.92 | ||
| 14-Day ATR (€) | 0.007697 | ||
| 20-Day SMA (€) | 0.6375 | ||
| 12-1 Month Momentum % | 4.1 | ||
| 52-Week Range (€) | 0.545 - 0.835 | ||
| Shares Outstanding (Mil) | 6,282.51 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
China Resources Pharmaceutical Group Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
China Resources Pharmaceutical Group Ltd Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| No Event Data | ||||
China Resources Pharmaceutical Group Ltd Frequently Asked Questions
What is China Resources Pharmaceutical Group Ltd(FRA:640)'s stock price today?
The current price of FRA:640 is €0.61. The 52 week high of FRA:640 is €0.84 and 52 week low is €0.55.
When is next earnings date of China Resources Pharmaceutical Group Ltd(FRA:640)?
The next earnings date of China Resources Pharmaceutical Group Ltd(FRA:640) is 2025-08-29 Est..
Does China Resources Pharmaceutical Group Ltd(FRA:640) pay dividends? If so, how much?
The Dividend Yield %  of China Resources Pharmaceutical Group Ltd(FRA:640) is 5.08% (As of Today), Highest Dividend Payout Ratio of China Resources Pharmaceutical Group Ltd(FRA:640) was 0.3. The lowest was 0.16. And the median was 0.18. The  Forward Dividend Yield % of China Resources Pharmaceutical Group Ltd(FRA:640) is 5.08%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers